Invesco
STOK icon

Invesco’s Stoke Therapeutics STOK Stock Holding History

Invesco’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Sell
67,660
-82,385
-55% -$2.64M ﹤0.01% 2534
2026
Q1 		$4.89M Sell
150,045
-109,498
-42% -$3.59M ﹤0.01% 2203
2025
Q4 		$8.24M Buy
259,543
+51,468
+25% +$1.55M ﹤0.01% 1977
2025
Q3 		$4.89M Buy
208,075
+167,868
+418% +$2.88M ﹤0.01% 2244
2025
Q2 		$456K Buy
40,207
+14,024
+54% +$133K ﹤0.01% 3195
2025
Q1 		$174K Buy
26,183
+14,118
+117% +$132K ﹤0.01% 3545
2024
Q4 		$133K Buy
+12,065
New +$148K ﹤0.01% 3587
2024
Q3 		– Sell
-437,136
Closed -$5.91M – 3878
2024
Q2 		$5.91M Buy
+437,136
New +$5.9M ﹤0.01% 2094
2022
Q2 		– Sell
-131,674
Closed -$2.77M – 4138
2022
Q1 		$2.77M Buy
+131,674
New +$2.64M ﹤0.01% 2651
2021
Q4 		– Sell
-9,325
Closed -$237K – 4101
2021
Q3 		$237K Buy
9,325
+1,323
+17% +$36.9K ﹤0.01% 3737
2021
Q2 		$269K Buy
+8,002
New +$283K ﹤0.01% 3677
2021
Q1 		– Sell
-25,329
Closed -$1.57M – 3938
2020
Q4 		$1.57M Buy
+25,329
New +$1.16M ﹤0.01% 2739

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco's STOK Position: Q2 2026 in Review

Invesco reduced its Stoke Therapeutics (STOK) stake by 55% in Q2 2026, selling an estimated $2.64M and leaving 67,660 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2534.

Invesco first reported a position in STOK in Q4 2020 and has held it in 12 quarters since. The position peaked at $8.24M in Q4 2025. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Invesco held 67,660 shares of Stoke Therapeutics worth $2.21M as of Q2 2026.
  • Invesco sold 82,385 Stoke Therapeutics shares in Q2 2026, an estimated $2.64M.
  • Stoke Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2534 holding.
  • Invesco first reported a position in Stoke Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • Invesco's Stoke Therapeutics position peaked at $8.24M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.